FDA, States Weigh In On Prescribing Naloxone with Opioids
On July 23, 2020 the FDA issued a Drug and Safety Communication to recommend providers include a prescription for naloxone (Narcan) to those patients who are considered to be at increased risk of opioid overdose. Further, states such as South Carolina which are seeing spikes in opioid overdoses are considering legislation to compel providers to include naloxone when prescribing an opioid to a patient.
Naloxone, an opioid antagonist, reverses the effects – including respiratory depression – of opioids. Considered a form of “harm reduction”, naloxone is readily available in multiple forms including intra-nasal for easy, convenient administration and commonly in most states without a prescription. For some patients, it may even be provided at no charge.